Age Range
18+
Trial Purpose
Lesi isifundo sesigaba sesi-3, esingahleliwe, esilawulwa yi-placebo sokusebenza nokuphepha kwe-enlicitide decanoate, i-oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, kubahlanganyeli abasengozini enkulu yenhliziyo nemithambo yegazi. Inhloso eyinhloko ukuhlola ukusebenza kahle kwe-enlicitide decanoate uma kuqhathaniswa ne-placebo ekwandiseni isikhathi sokuvela kokuqala kwezehlakalo ezimbi kakhulu zenhliziyo nemithambo yegazi (MACE) okuhlanganisa ukufa kwe-coronary heart disease (CHD), ischemic stroke, myocardial infarction (MI), i-acute limb ischemia noma ukunqunywa okukhulu kwemithambo, noma ukuvuselelwa kabusha kwemithambo ephuthumayo.
NATIONAL TRIAL REFERENCE NUMBER
I-NCT06008756
EU CT Number
2022-502781-24-00
When speaking to your doctor or clinical trial representative, please have the trial reference number available.
About The Study
Trial Phase
Trial start and end dates
- Actual study start date Okthoba 9, 2023
- Estimated primary completion date Novemba 29, 2029
- Estimated study completion date Novemba 29, 2029
Trial locations
Sorry, there are no locations found.